A significant jump in plant-propagation sales and medical marijuana exports helped Canadian licensed producer Aurora Cannabis narrow its loss in the first quarter of fiscal year 2024 to 28.3 million Canadian dollars ($20 million).
Canadian marijuana producer Aurora Cannabis closed on the sale of its enormous Sun greenhouse to Bevo Farms, although the exact value of the transaction was not disclosed.
Aurora Cannabis reported a loss of 87 million Canadian dollars ($65 million) for the three months ended March 31, 2023, up slightly from the CA$67.2 million net loss reported in the previous quarter.
Canadian producer Aurora Cannabis is closing its remaining facility in Denmark and moving production to Canada in a bid to lower costs.
Aurora Cannabis has been notified by the Nasdaq that it does not meet the stock exchange’s listing standards after its stock price fell below the $1 minimum bid price requirement for 30 days in a row.
Aurora Cannabis CEO Miguel Martin discusses his role in the “transformation” of the company from a money-losing venture to one on the upswing.
Edmonton, Alberta-based Aurora Cannabis posted positive adjusted earnings before EBITDA worth 1.4 million Canadian dollars ($1 million) in its second fiscal quarter of the year, the company announced late Thursday.
Canadian marijuana producer Aurora Cannabis sold off its former Aurora Polaris facility to an unspecified buyer for gross proceeds of 15 million Canadian dollars ($11.1 million).
Canadian marijuana company Aurora Cannabis is continuing its debt-reduction quest, repurchasing roughly 103 million Canadian dollars ($76.1 million) worth of convertible notes.
Canadian producer Aurora Cannabis reported a net loss of 51.9 million Canadian dollars ($39.1 million) for the first quarter of its 2023 fiscal year.
Canadian marijuana company Aurora Cannabis reduced its debt load by repurchasing roughly 31.3 million Canadian dollars ($23 million) worth of its convertible senior notes.
Aurora Cannabis reported another significant quarterly and annual loss, but the Alberta-based marijuana producer said it’s on track to report a profit next year on the back of strong growth in the European medical market.
